
PRE Stock Forecast & Price Target
PRE Analyst Ratings
Bulls say
Prenetics Global is supported by a rapidly scaling IM8 franchise that has reached about $200 million in ARR as of May 31 and generated preliminary record revenue of about $17 million in June, while 1Q26 total revenue from continuing operations rose 333% year over year to $36 million. Its fundamentals are strengthened by a $1 billion growth financing that funds up to 70% of IM8 marketing spend without dilution, plus an estimated $139.7 million in cash and investments, easing balance-sheet risk and improving capital efficiency. The brand also benefits from clinically validated, NSF Certified for Sport products, a 3:1 LTV/CAC, and quarterly subscriptions that have lifted AOV to $240 and accelerated cash collection, supporting FY26 revenue guidance of $210-$220 million and expected FY27 revenue above $400 million.
Bears say
Prenetics Global is a high-risk consumer wellness company whose growth depends on turning one-time buyers into recurring subscribers, yet its business remains exposed to churn, changing consumer preferences, and intense competition in the nutritional supplement market. Its IM8 model also carries heavy operating pressure from sales and marketing, global freight and fulfillment costs, and potentially rising customer acquisition costs, even as only about 80% of all new IM8 orders as of December 31, 2025 were subscription-based. In addition, the lack of FDA approval for dietary supplements, geopolitical and supply-chain exposure tied to Hong Kong and China, and concentrated control by Chairman and CEO Danny Yeung with more than 50% voting power create regulatory, governance, and execution risks that could limit long-term profitability.
This aggregate rating is based on analysts' research of Prenetics Global Ltd and is not a guaranteed prediction by Public.com or investment advice.
PRE Analyst Forecast & Price Prediction
Start investing in PRE
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Prenetics Global Ltd (PRE) Forecast
PRE Analyst Forecast & Price Prediction
Start investing in PRE
Order type
Buy in
Order amount
Est. shares
0 shares